Reversal of Latency as Part of a Cure for HIV-1

Trends in Microbiology

Volumn 24, Issue 2, 2016, Pages 90-97

  Rasmussen, Thomas Aagaard ^a   Tolstrup, Martin ^a   Søgaard, Ole Schmeltz ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Clinical research; Histone deacetylase inhibitors; HIV 1 cure; HIV 1 latency; HIV 1 reservoir; Latency reversing agents

Indexed keywords

DISULFIRAM; PANOBINOSTAT; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

COMBINATION CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EVASION; IMMUNE RESPONSE; LATENT VIRUS INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS EXPRESSION; VIRUS LATENCY; VIRUS MUTATION; VIRUS REACTIVATION; ANIMAL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; VIRUS LATENCY;

EID: 84959168303     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.11.003     Document Type: Review

References (60)

1. Perelson A.S., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
2. Chun T.W., et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13193-13197.
3. Finzi D., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
4. Siliciano R.F., Greene W.C. HIV latency. Cold Spring Harb. Perspect. Med. 2011, 1:a007096.
5. Anderson J.L., et al. Entry of HIV in primary human resting CD4(+) T cells pretreated with the chemokine CCL19. AIDS Res. Hum. Retroviruses 2014, 30:207-208.
6. Eisele E., Siliciano R.F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012, 37:377-388.
7. Deeks S.G. HIV: Shock and kill. Nature 2012, 487:439-440.
8. Shang H.T., et al. Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacol. Sin. 2015, 36:908-916.
9. Darcis G., et al. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to potently reactivate viral gene expression. PLoS Pathog. 2015, 11:e1005063.
10. Lehrman G., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
11. + T cells. AIDS 2008, 22:1131-1135.
12. + cell infection. PLoS ONE 2010, 5:e9390.
13. Routy J.P., et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012, 13:291-296.
14. Archin N.M., et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.
15. + T cells after multiple doses of vorinostat. J. Infect. Dis. 2014, 210:728-735.
16. Spivak A.M., et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 2014, 58:883-890.
17. Rasmussen T.A., et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single-group, clinical trial. Lancet HIV 2014, 1:e13-e21.
18. Elliott J.H., et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014, 10:e1004473.
19. Sogaard O.S., et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015, 11:e1005142.
20. Elliott J., et al. Short-term disulfiram to reverse latent HIV infection: A dose escalation study. Lancet HIV 2015, 2:e520-e529.
21. Stellbrink H.J., et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002, 16:1479-1487.
22. + T cell depletion. J. Clin. Immunol. 2001, 21:218-226.
23. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 1999, 5:651-655.
24. Archin N.M., et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 2009, 25:207-212.
25. Matalon S., et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune. Defic. Syndr. 2010, 54:1-9.
26. Mann B.S., et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
27. + T cell model without inducing global T cell activation. J. Virol. 2011, 85:6060-6064.
28. Rasmussen T.A., et al. Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. Hum. Vaccines Immunother. 2013, 9:993-1001.
29. Laubach J.P., et al. Panobinostat for the treatment of multiple myeloma. Clin. Cancer Res. 2015, 21:4767-4773.
30. Shan L., et al. Stimulation of HIV-1-specific cytolytic t lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
31. + T cells. AIDS 2015, 29:2235-2244.
32. Hersperger A.R., et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010, 6:e1000917.
33. Borrow P., et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 1997, 3:205-211.
34. Deng K., et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 2015, 517:381-385.
35. Yukl S.A., et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J. Infect. Dis. 2010, 202:1553-1561.
36. Chun T.W., et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 2008, 197:714-720.
37. Churchill M.J., et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann. Neurol. 2009, 66:253-258.
38. Rasmussen T.A., et al. Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect. Dis. 2015, 2:ofv037.
39. Barton K.M., et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS ONE 2014, 9:e102684.
40. Wei D.G., et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014, 10:e1004071.
41. Doyon G., et al. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 2013, 27:F7-F11.
42. Williams S.A., et al. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J. Virol. 2007, 81:6043-6056.
43. Salminen A., Kaarniranta K. Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal. 2010, 22:573-577.
44. Laird G.M., et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J. Clin. Invest. 2015, 125:1901-1912.
45. Ramsdell J.S., et al. Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells. J. Biol. Chem. 1986, 261:17073-17080.
46. Plimack E.R., et al. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. Oncologist 2014, 19:354-355.
47. Jiang G., et al. Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS Pathog. 2015, 11:e1005066.
48. + T cells from aviremic patients. Antimicrob. Agents Chemother. 2015, 59:5984-5991.
49. Boehm D., et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2013, 12:452-462.
50. Pache L., et al. BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by Smac mimetics to promote reversal of viral latency. Cell Host Microbe 2015, 18:345-353.
51. Winckelmann A.A., et al. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS ONE 2013, 8:e62074.
52. Bullen C.K., et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 2014, 20:425-429.
53. Reuse S., et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 2009, 4:e6093.
54. Caskey M., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015, 522:487-491.
55. Halper-Stromberg A., et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014, 158:989-999.
56. Hansen S.G., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
57. Sung J.A., et al. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 2015, 125:4077-4090.
58. Pegu A., et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat. Commun. 2015, 6:8447.
59. Badley A.D., et al. Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis. 2013, 4:e718.
60. Porichis F., et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011, 118:965-974.